Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A convenient synthetic route towards H-bisphosphinates.

Dussart J, Guedeney N, Deschamp J, Monteil M, Gager O, Legigan T, Migianu-Griffoni E, Lecouvey M.

Org Biomol Chem. 2018 Oct 3;16(38):6969-6979. doi: 10.1039/c8ob01878b.

PMID:
30229797
2.

Multivalency To Inhibit and Discriminate Hexosaminidases.

Alvarez-Dorta D, King DT, Legigan T, Ide D, Adachi I, Deniaud D, Désiré J, Kato A, Vocadlo D, Gouin SG, Blériot Y.

Chemistry. 2017 Jul 6;23(38):9022-9025. doi: 10.1002/chem.201701756. Epub 2017 Jun 20.

PMID:
28548311
3.

Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers.

Renoux B, Raes F, Legigan T, Péraudeau E, Eddhif B, Poinot P, Tranoy-Opalinski I, Alsarraf J, Koniev O, Kolodych S, Lerondel S, Le Pape A, Clarhaut J, Papot S.

Chem Sci. 2017 May 1;8(5):3427-3433. doi: 10.1039/c7sc00472a. Epub 2017 Mar 8.

4.

Active Esters as Pseudostoppers for Slippage Synthesis of [2]Pseudorotaxane Building Blocks: A Straightforward Route to Multi-Interlocked Molecular Machines.

Legigan T, Riss-Yaw B, Clavel C, Coutrot F.

Chemistry. 2016 Jun 20;22(26):8835-47. doi: 10.1002/chem.201601286. Epub 2016 May 30.

PMID:
27239975
5.

Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent α-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors.

Cendret V, Legigan T, Mingot A, Thibaudeau S, Adachi I, Forcella M, Parenti P, Bertrand J, Becq F, Norez C, Désiré J, Kato A, Blériot Y.

Org Biomol Chem. 2015 Nov 21;13(43):10734-44. doi: 10.1039/c5ob01526j.

PMID:
26356422
6.

Erratum to: Surface functionalization by covalent immobilization of an innovative carvacrol derivative to avoid fungal biofilm formation.

Gharbi A, Legigan T, Humblot V, Papot S, Imbert C, Berjeaud JM.

AMB Express. 2015 Dec;5(1):141. doi: 10.1186/s13568-015-0141-4. Epub 2015 Aug 21. No abstract available.

7.

Surface functionalization by covalent immobilization of an innovative carvacrol derivative to avoid fungal biofilm formation.

Gharbi A, Legigan T, Humblot V, Papot S, Berjeaud JM.

AMB Express. 2015 Feb 5;5:9. doi: 10.1186/s13568-014-0091-2. eCollection 2015. Erratum in: AMB Express. 2015 Dec;5(1):141.

8.

A mechanically interlocked molecular system programmed for the delivery of an anticancer drug.

Barat R, Legigan T, Tranoy-Opalinski I, Renoux B, Péraudeau E, Clarhaut J, Poinot P, Fernandes AE, Aucagne V, Leigh DA, Papot S.

Chem Sci. 2015 Apr 1;6(4):2608-2613. doi: 10.1039/c5sc00648a. Epub 2015 Feb 25.

9.

Design and synthesis of α-carboxy nucleoside phosphonate analogues and evaluation as HIV-1 reverse transcriptase-targeting agents.

Keane SJ, Ford A, Mullins ND, Maguire NM, Legigan T, Balzarini J, Maguire AR.

J Org Chem. 2015 Mar 6;80(5):2479-93. doi: 10.1021/jo502549y. Epub 2015 Jan 9.

PMID:
25532055
10.

Evaluation of cytotoxic properties of a cyclopamine glucuronide prodrug in rat glioblastoma cells and tumors.

Bensalma S, Chadeneau C, Legigan T, Renoux B, Gaillard A, de Boisvilliers M, Pinet-Charvet C, Papot S, Muller JM.

J Mol Neurosci. 2015 Jan;55(1):51-61. doi: 10.1007/s12031-014-0395-3. Epub 2014 Oct 4.

PMID:
25280457
11.

Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.

Balbous A, Renoux B, Cortes U, Milin S, Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, Karayan-Tapon L.

Mol Cancer Ther. 2014 Sep;13(9):2159-69. doi: 10.1158/1535-7163.MCT-13-1038. Epub 2014 Jul 22.

12.

β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.

Tranoy-Opalinski I, Legigan T, Barat R, Clarhaut J, Thomas M, Renoux B, Papot S.

Eur J Med Chem. 2014 Mar 3;74:302-13. doi: 10.1016/j.ejmech.2013.12.045. Epub 2014 Jan 11.

PMID:
24480360
13.

An enzyme-responsive system programmed for the double release of bioactive molecules through an intracellular chemical amplification process.

Grinda M, Legigan T, Clarhaut J, Peraudeau E, Tranoy-Opalinski I, Renoux B, Thomas M, Guilhot F, Papot S.

Org Biomol Chem. 2013 Nov 7;11(41):7129-33. doi: 10.1039/c3ob41536h.

PMID:
24057011
14.

Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.

Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, Jayle C, Alsarraf J, Thomas M, Papot S.

Eur J Med Chem. 2013 Sep;67:75-80. doi: 10.1016/j.ejmech.2013.06.037. Epub 2013 Jun 25.

PMID:
23845743
15.

The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.

Legigan T, Clarhaut J, Tranoy-Opalinski I, Monvoisin A, Renoux B, Thomas M, Le Pape A, Lerondel S, Papot S.

Angew Chem Int Ed Engl. 2012 Nov 12;51(46):11606-10. doi: 10.1002/anie.201204935. Epub 2012 Sep 20.

PMID:
22996951
16.

Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.

Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, Berjeaud JM, Guilhot F, Papot S.

J Med Chem. 2012 May 10;55(9):4516-20. doi: 10.1021/jm300348r. Epub 2012 Apr 30.

PMID:
22515366
17.

A new cyclopamine glucuronide prodrug with improved kinetics of drug release.

Renoux B, Legigan T, Bensalma S, Chadéneau C, Muller JM, Papot S.

Org Biomol Chem. 2011 Dec 21;9(24):8459-64. doi: 10.1039/c1ob06081c. Epub 2011 Oct 31.

PMID:
22042246

Supplemental Content

Loading ...
Support Center